Adjuvant Therapy for Gallbladder Cancer: an Analysis of the National Cancer Data Base

Abstract

ACR is associated with improved survival for patients with node-positive GBC, as well as those with T2 or T3 GBC with unknown lymph node status.

Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis

“…25 Other investigators have similarly argued that adjuvant cXRT provides an incremental survival benefit over CTx alone. 21 Collectively, data from the current study as well as previous reports suggest that administration of systemic CTx with the integration of cXRT may be the optimal adjuvant strategy for patients with resected GBC characterized by high-risk features. 1,5,9,26 …”

“…9 Other observational studies have similarly demonstrated that the benefit of adjuvant therapy for GBC is most pronounced among that subset patients with ≥T2, N1, and R1 disease. 3,11,21,25 …”

Impact of chemotherapy and external beam radiation therapy on outcomes among patients with resected gallbladder cancer: A multi-institutional analysis.

“…25 Other investigators have similarly argued that adjuvant cXRT provides an incremental survival benefit over CTx alone. 21 Collectively, data from the current study as well as previous reports suggest that administration of systemic CTx with the integration of cXRT may be the optimal adjuvant strategy for patients with resected GBC characterized by highrisk features. 1,5,9,26 Several limitations should be considered when interpreting the data.…”

“…The role of adjuvant therapy for GBC remains unclear and somewhat controversial. 16,21 Most previous studies were limited due to small sample size, single institutional experiences, as well as heterogeneous study populations. 11,18,19,22 The current study is important because it reports one of the largest, multi-institutional experiences on the surgical management of GBC in the United States.…”

“…9 Other observational studies have similarly demonstrated that the benefit of adjuvant therapy for GBC is most pronounced among that subset patients with ≥T2, N1, and R1 disease. 3,11,21,25 Radiotherapy is commonly administered with concurrent chemotherapy, and most studies that have reported a benefit of adjuvant radiotherapy included patients treated with concurrent chemotherapy. 1,4,16 As noted in the current study, the locoregional benefit of adjuvant cXRT may be only relevant when systemic control of disease also is addressed, as the majority of recurrences (86 %) were distant in nature.…”